$89.21
0.02% today
NYSE, Mar 31, 08:44 pm CET
ISIN
US58933Y1055
Symbol
MRK

Merck & Co. Stock price

$89.23
-3.02 3.27% 1M
-24.33 21.42% 6M
-10.25 10.30% YTD
-42.72 32.38% 1Y
+8.02 9.88% 3Y
+15.86 21.61% 5Y
+33.60 60.40% 10Y
NYSE, Closing price Fri, Mar 28 2025
+1.63 1.86%
ISIN
US58933Y1055
Symbol
MRK
Sector
Industry

Key metrics

Market capitalization $225.40b
Enterprise Value $249.96b
P/E (TTM) P/E ratio 13.25
EV/FCF (TTM) EV/FCF 13.81
EV/Sales (TTM) EV/Sales 3.91
P/S ratio (TTM) P/S ratio 3.52
P/B ratio (TTM) P/B ratio 4.87
Dividend yield 3.50%
Last dividend (FY24) $3.12
Revenue growth (TTM) Revenue growth 6.85%
Revenue (TTM) Revenue $63.97b
EBIT (operating result TTM) EBIT $21.35b
Free Cash Flow (TTM) Free Cash Flow $18.10b
Cash position $13.77b
EPS (TTM) EPS $6.73
P/E forward 10.46
P/S forward 3.46
EV/Sales forward 3.83
Short interest 1.47%
Show more

Create a Free Account to create an Merck & Co. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Merck & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Merck & Co. forecast:

18x Buy
67%
9x Hold
33%

Analyst Opinions

27 Analysts have issued a Merck & Co. forecast:

Buy
67%
Hold
33%

Financial data from Merck & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
63,973 63,973
7% 7%
100%
- Direct Costs 16,197 16,197
9% 9%
25%
47,776 47,776
13% 13%
75%
- Selling and Administrative Expenses 6,274 6,274
4% 4%
10%
- Research and Development Expense 15,726 15,726
45% 45%
25%
25,776 25,776
273% 273%
40%
- Depreciation and Amortization 4,431 4,431
14% 14%
7%
EBIT (Operating Income) EBIT 21,345 21,345
601% 601%
33%
Net Profit 17,117 17,117
4,590% 4,590%
27%

In millions USD.

Don't miss a Thing! We will send you all news about Merck & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merck & Co. Stock News

Neutral
GlobeNewsWire
about 2 hours ago
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).
Neutral
PRNewsWire
3 days ago
NEW YORK , March 28, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Positive
The Motley Fool
3 days ago
Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, biotechnology giant Amgen (AMGN 0.06%) has been the best-performing stock in 2025, returning an impressive 21% year to date.
More Merck & Co. News

Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Head office United States
CEO Robert Davis
Employees 75,000
Founded 1891
Website www.merck.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today